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Abstract
Background: The natural compound triptolide has been shown to decrease cell proliferation and induce apoptosis
and cellular senescence. We previously demonstrated that triptolide decreases tumor formation and metastasis of
human non-small cell lung cancer cells (NSCLC). Due to the toxicity of triptolide, derivatives of the natural compound
have been developed that show more favorable toxicity profiles and pharmacokinetics in animal models. The purpose
of this study was to evaluate MRx102 as a novel therapeutic for lung cancer.
Methods: Mice injected subcutaneously with H460 lung cancer cells were treated with MRx102 or carboplatin to
determine the effect of MRx102 on tumor formation in comparison to standard treatment. Patient-derived xenografts
(PDX) with different WIF1 expression levels were treated with MRx102 or cisplatin. We tested the effects of MRx102
treatment on migration and invasion of lung cancer cells using Transwell filters coated with fibronectin and Matrigel,
respectively. Tail vein injections using H460 and A549 cells were performed.
Results: Here we report that the triptolide derivative MRx102 significantly decreases NSCLC proliferation and stimulates
apoptosis. Further, MRx102 potently inhibits NSCLC haptotactic migration and invasion through Matrigel. In vivo, NSCLC
tumor formation and metastasis were greatly decreased by MRx102 treatment. The decrease in tumor formation by
MRx102 in the patient-derived xenograft model was WIF1-dependent, demonstrating that MRx102 is a potent inhibitor
of the Wnt pathway in low WIF1 expressing NSCLC patient tumors.
Conclusions: These results indicate that MRx102 has potent antitumor effects both in vitro and in vivo, and is a
potential novel therapy for the treatment of NSCLC.
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Background
Lung cancer is the leading cause of cancer-related deaths
world-wide in both men and women [1]. The carcino-
genic toxins in cigarette smoke that create inflammation
and accumulation of somatic mutations in the cellular
DNA have been implicated as the leading cause of lung
cancer development [2, 3]. Non-small cell lung cancer
(NSCLC) is the most common type of lung cancer com-
prising approximately 85 % of lung cancer diagnoses [4].
NSCLC that is discovered early is often treated through
resection and adjuvant therapy involving a platinum
agent [5]. Advanced disease is treated with palliative
platinum based chemotherapy [6]. Only about 10 % of
patients with NSCLC will harbor molecular changes ren-
dering their tumor sensitive to an approved targeted
agent. While a number of new targeted agents are being
investigated, therapies that have novel mechanisms of
actions are urgently needed for lung cancer patients [7].
Triptolide is a natural compound isolated from the
Thunder God Vine, Tripterygium wilfordii, which has
been used in traditional Chinese medicine to treat auto-
immune disorders and inflammation, including lupus
and rheumatoid arthritis [8]. Triptolide also has potent
anti-tumor activity in a variety of cancers, including lung
cancer [9, 10]. Triptolide perturbs multiple signaling
pathways including NFkB, HSP70, and p53 pathways,
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which decreases cell proliferation and induces apoptosis
[11–13]. In lung cancer, triptolide has been shown to
sensitize cells to TRAIL-induced apoptosis and enhance
p53 activity [14]. We previously showed that triptolide in-
hibits the Wnt pathway in lung cancer via overexpression
of Wnt inhibitory factor 1 (WIF1), which is silenced in
most lung cancers by promoter hypermethylation. Though
triptolide has anti-tumor effects, its clinical use is limited
by toxicity and unfavorable pharmacokinetics [15]. Re-
cently, triptolide derivatives have been developed in order
to optimize bioavailability with decreased toxicity.
The triptolide derivative MRx102 (MyeloRx, Vallejo,
CA) has been previously shown to have antileukemic ac-
tivity both in vitro and in vivo by promoting apoptosis
of AML cells and can overcome the protection garnered
by the microenvironment [16]. Though MRx102 de-
creases tumorgenicity of blood malignancies, its effect
on lung cancer is unknown. To determine the potential
of MRx102 as a novel therapeutic for lung cancer, we in-
vestigated the effect of MRx102 on the proliferation, sur-
vival, and migration of NSCLC cell lines in vitro and the
effect on tumor formation and metastasis in vivo. We
found that MRx102 significantly decreases Wnt pathway
activation, cell proliferation, migration, and invasion in
H460 and A549 cells. In addition, both tumor formation
and metastasis were inhibited in murine models, includ-
ing a patient derived xenograft (PDX) NSCLC model.
Methods
Reagents and antibodies
Dulbecco’s Modified Eagle Medium (DMEM) was pur-
chased from Life Technologies (Carlsbad, CA). 8.0 micron
Transwell dishes with Matrigel coating for invasion assays
or without ECM coating for the migration assays were
purchased from BD Biosciences (San Jose, CA). MRx102
was a kind gift from MyeloRx LLC (Vallejo, CA).
WIF1 antibody (MABN722) was purchased from
EMD/Millipore (Temecula, CA). The GAPDH, phos-
pho β-catenin, and total β-catenin, and p53 antibodies
were purchased from Cell Signaling (Danvers, MA). The
phosphor Akt and total Akt antibodies were purchased from
Santa Cruz Biotechnology (Dallas, TX). HRP-conjugated
goat anti-rabbit and goat anti-mouse secondary antibody
were purchased from Genetex (Irvine, CA).
Cell culture and drug treatment methods
H460 and A549 human NSCLC cells were acquired from
ATCC and cultured in 5 % CO2 at 37 °C in DMEM con-
taining 10 % FBS, 1 % sodium pyruvate, 1 % L-glutamine/
gentamycin and 1 % penicillin/streptomycin (complete
medium).
MRx102 (MyeloRx, Vallejo, CA) was diluted with DMSO
and a 10nM concentration for use in the in vitro assays un-
less otherwise indicated.
Annexin V staining for apoptosis
Analysis of apoptosis was conducted using the AnnexinV-
FITC Apoptosis Detection Kit from Life Technologies
(Carlsbad, CA) according to the manufacturer’s protocol.
Briefly, control and triptolide treated H460 and A549 cells
were harvested after 48 h and washed with PBS and Bind-
ing Buffer. The cells were then labeled with AnnexinV-
FITC for 15 min and washed and resuspended in Binding
Buffer. Propidium Iodide staining solution was added to
the resuspended cells to check for viability. Stained cells
were examined using a CyAn flow cytometer (Beckman
Coulter, Brea, CA). The FlowJo analysis software was used
to analyze the percentage of cells undergoing apoptosis.
RT-PCR
RNA was isolated using the Purelink RNA Mini kit from
Life Technologies (Carlsbad, CA) according to the manu-
facturer’s protocol. The RNA was then reverse transcribed
to cDNA using the High-Capacity cDNA Reverse Tran-
scription kit from Applied Biosystems (Grand Island, NY)
according to the manufacturer’s protocol. The RT-PCR
was performed using Taqman gene-specific probes (Ap-
plied Biosystems) with Taqman Fast Universal Master Mix
(Life Technologies) according to the published protocol
using the Viia7 RT-PCR machine (Applied Biosystems).
The GAPDH RNA expression was used to normalize the
WIF1 levels.
Western blotting
Immunoblotting was performed using nitrocellulose
membranes and 4–12 % Bis-Tris Nupage gels from Life
Technologies (Carlsbad, CA). The membranes were
blocked with 5 % non-fat milk before the addition of the
primary antibody.
Migration and invasion assays
Migration was analyzed using Transwell filters coated with
5 μg/ml fibronectin on the bottom of the filter (haptotaxis).
Control or MRx102 treated cells (1×105) were added to the
top of the filter and allowed to migrate for 6 h. Cells
remaining on top of the filter were removed. The migrated
cells were fixed in 4 % paraformaldehyde and the filter was
mounted in Prolong Gold with DAPI on a microscope
slide. Migration and invasion was analyzed using fluores-
cence microscopy. The assay was completed three times in
triplicate and nine random images were obtained per filter.
Invasion assays were performed as previously described
and DAPI was used to visualize the cellular nuclei [17].
Top flash luciferase assay
Transient transfections were performed with polyethyle-
nimine transfection reagent (Sigma, St. Louis, MO) on
1×105 H460 and A549 cells that were plated in a 24-well
plate. In the corresponding wells, 0.5 μg of the TOP-
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FLASH or FOP-FLASH firefly luciferase reporter plasmid
and, as an internal control, 0.05 ug of the Renilla lucifer-
ase reporter pTK (Promega, Madison, WI) was used. After
24 h, DMSO as a control or 10nM MRx102 was added to
the corresponding wells. After 48 h of treatment, the cell
lysate was collected and the luciferase activity was deter-
mined using the Dual Luciferase Assay System (Promega,
Madison, WI) and a luminonmeter. The firefly luciferase
activity was normalized to the Renilla luciferase activity.
Bisulfite conversion of genomic DNA and methylation
analysis
Genomic DNA from control and MRx102 treated (96 h)
A549 and H460 cells was extracted using the QIAamp
DNA mini-kit (Qiagen, Valenica, CA) according to the
manufacturer’s protocol. 400 ng of the genomic DNA
was used for bisulfite conversion. The bisulfite conver-
sion was carried out using the EZ DNA Methylation-
Lightning kit (Zymo Research, Irvine, CA) according to
the manufacturer’s published protocol. 5 ul of the bisul-
fite converted DNA was used for PCR analysis with
primers specific for the methylated and unmethylated
versions of the WIF1 promoter region. The PCR product
was then run on a 2 % agarose gel and imaged using











Fluorescence and brightfield imaging were performed
using a Zeiss Axio Observer Z1 inverted microscope
equipped with Axiocam MRc5 (brightfield) and Hama-
matsu Orca CCD (fluorescence) cameras.
Animal studies
Subcutaneous Xenograft Mouse Model - H460 human
lung cancer cells (5×105) were injected into the hind flank
of 4–8 week old NSG mice. The mice were monitored for
tumor growth. Treatment was started when tumors
reached 50–100 mm3 by measurement with calipers. Mice
were split into groups of at least nine mice and treated as
indicated with either control (PBS) five times per week,
triptolide (0.5 mg/kg) three times per week, MRx102
(1, 2, 3, or 4 mg/kg) five times per week, carboplatin
(15 mg/kg) once per week, or a combination of MRx102
(2 mg/kg) and carboplatin (15 mg/kg) once per week, by
interperitoneal injection (IP). Tumors were harvested
when the tumors in the control group began to reach
1500 mm3 (approximately two and half weeks).
Patient-Derived Xenograft Mouse Model – Human
lung cancer tissue was obtained from research partici-
pants at the time of surgical resection of lung cancer.
The tissue was collected fresh and was immediately
dissected, minced into tissue blocks at about 3 mm in
diameter and placed in saline with antibiotics. NSG mice at
6–10 weeks old were anesthetized by isoflurane inhalation.
The dorsal area of NSG mice was shaved and prepared with
a povidine-iodine/alcohol solution. A small cut was made
in the prepared skin and a pocket under skin was created
using a pair of forceps. The human cancer tissue blocks
were transplanted into this subcutaneous dorsal skin com-
partment of the NSG mice. The wound was closed by using
skin glue. Once the tumors reached a sufficient size, the
tissue was passaged into another group of NSG mice. On
the third passage, and once tumors reached 100 mm3 (as
measured by calipers) treatment was started as indicated
with either control (PBS) five times per week, MRx102
(3 mg/kg) five times per week, cisplatin (6 mg/kg) once per
week, or a combination of MRx102 (3 mg/kg) and cisplatin
(6 mg/kg) once per week, by IP injection with at least seven
mice per treatment group. Tumors were harvested when
control tumors began to approach the 1500 mm3 max-
imum (approximately 3 weeks). Tumors were stained for
Wnt3a expression by a participating pathologist (SWT).
One high Wnt3a and one low Wnt3a lung adenocarcinoma
PDX model was selected for these experiments.
Tail Vein Injection Mouse Model - H460 (5×104) and
A549 (1×105) cells were injected into the tail vein of 6–
8 week old NSG mice. After 2 weeks the mice began to re-
ceive control (PBS) or MRx102 (3 mg/kg) by IP injection
three times a week for 8 weeks with at least eight mice per
group. Mice were then euthanized and the lungs and liver
were harvested, fixed in 10 % formalin, and paraffin em-
bedded for pathological examination of H&E slides.
The NSG mice used for these studies were bred at the
City of Hope Medical Center animal facility.
Statistical analysis
All quantified data were plotted and analyzed in GraphPad
Prism 6.0 using a Student t-test or one-way Anova with
Tukey post test. Data are representative of at least 3 inde-
pendent experiments as replicate means ± SEM. ** or ***
are p values < 0.01, or 0.001, respectively.
Results
MRx102 decreases NSCLC cell proliferation and colony
formation and increases apoptosis
Triptolide has antiproliferative effects in a variety of can-
cer cell lines [9]. To assess the ability of the triptolide de-
rivative MRx102 to decrease lung cancer cell proliferation,
Reno et al. BMC Cancer  (2016) 16:439 Page 3 of 10
we treated H460 and A549 human NSCLC cells with in-
creasing concentrations of MRx102. After 48 h, MRx102
significantly decreases both H460 and A549 lung cancer
cell proliferation in a concentration dependent manner
(Fig. 1a). To further study the effectiveness of MRx102 on
the proliferation and survival of lung cancer cells, we con-
ducted a colony formation assay with varying concentra-
tions of MRx102. Colony formation of A549 and H460
cells was significantly inhibited by MRx102 treatment with
a decrease in both colony number and size as the concen-
tration of MRx102 was increased (Fig. 1b). Next, we
wanted to determine if treatment with MRx102 sensitizes
cancer cells to apoptosis. After treatment with 10nM
MRx102 for 48 h, the percentage of early apoptotic (high
Annexin V-488 and low PI staining), late apoptotic (high
Annexin V-488 and high PI staining), and necrotic (low
Annexin V-488 and high PI staining) cells was determined
using FACS analysis. When compared to control cells
treated with DMSO, the MRx102 treated H460 cells had
significantly higher populations of early apoptotic, late
apoptotic, and necrotic cells (Fig. 1c, left). This effect was
less notable in the A549 cell line suggesting that MRx102
has less of an effect on apoptotic programming in this cell
line or a longer incubation period with the drug is needed
to see an effect (Fig. 1c, right). Due to the increase in
apoptosis, we looked at p53 and Akt activation, which are
known to be involved in cell death and survival. There was
a dose dependent increase in p53 expression after MRx102
treatment and slight decrease in phospho Akt levels after
treatment at a 10nM concentration of MRx102 (Fig. 1d).
This data suggests that MRx102 might regulate cell sur-
vival and death by modulation of the p53 and Akt path-
ways. The decrease in cell proliferation and increase in
apoptosis in vitro led us to evaluate the effect of MRx102
on lung cancer cell growth in vivo.
NSCLC tumor formation and growth is inhibited by
MRx102
To investigate the effect of MRx102 on lung cancer cell
growth in vivo, we subcutaneously injected H460 human
NSCLC cells in the hind flank of 6–8 week old NSG
mice. After treatment with 1 mg/kg MRx102, there was
a significant decrease in both tumor volume (p = .0153)




Fig. 1 MRx102 decreases lung cancer cell proliferation and increases apoptosis. a Cell proliferation assay and corresponding quantification of cell
number for H460 (top panel) and A549 (bottom panel) cells treated with MRx102 (0-100nM). b Colony formation assay with quantification of
colony number for H460 (top) and A549 (bottom) cells treated with MRx102 (0, 1, 3 nM top row and 10, 30, 100nM bottom row). Annexin V/PI staining
of H460 (c-left) and A549 (c-right) cells. Quadrants are as follows: Top-left – dead/necrotic cells, Top-right – Late apoptotic cells, Bottom-right – Early
apoptotic cells, and Bottom-left – Live cells. d Western blot analysis of p53 expression and Akt activation in H460 and A549 cells. *** represents a
p value of <0.001 as determined by a Student T-test
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mice (Fig. 2a, b and c). It has been shown that triptolide
treatment can lead to the decrease in tumor formation
in mice [18]. The decrease in tumor burden by MRx102
after subcutaneous H460 injection was similar to the
effects of triptolide treatment (Fig. 2b). This data sug-
gests that MRx102 has anti-tumor activity in vivo that is
comparable to the effects already seen in studies using
triptolide.
MRx102 has additive effects with Carboplatin in the
xenograft mouse model
Platinum agents, including carboplatin and cisplatin, have
been used as standard components of NSCLC chemother-
apeutic regimens [5]. Based on the ability of MRx102 to
decrease NSCLC tumor formation in mice, we treated
mice harboring subcutaneous H460 tumors with increas-
ing concentrations of MRx102 (2, 3, and 4 mg/kg), 15 mg/
kg carboplatin, or a combination of 2 mg/kg MRx102 and
15 mg/kg carboplatin to compare the efficacy of MRx102
with the standard NSCLC platinum therapy (Fig. 3a).
Treating with 2, 3 or 4 mg/kg MRx102 had similar effects
compared to treating with 15 mg/kg carboplatin decreasing
tumor size by more than half (p < .0001) (Fig. 3b) and redu-
cing tumor weight (p < .0001) (Fig. 3c). When combined,
2 mg/kg MRx102 and 15 mg/kg carboplatin appeared to
have an additive effect on decreasing tumor formation in
mice (Fig. 3b and c).
MRx102 treatment inhibits lung cancer growth in a low
WIF1 expressing PDX model of NSCLC
Wnt pathway alterations significantly contribute to lung
cancer progression and overexpression of Wnt pathway
molecules has been associated with poor prognosis in
NSCLC [19, 20]. We previously found that triptolide in-
hibits Wnt pathway activity through increased WIF1 ex-
pression. To test the affect of MRx102 on Wnt pathway
activity, we conducted a TOP-Flash luciferase assay. In
both H460 and A549 cells, luciferase activity decreased
after treatment with MRx102 suggesting that treatment
with this drug decreases Wnt pathway activation (Fig. 4a).
Because we found that treatment with MRx102 decreases
Wnt pathway activation in NSCLC cell lines, we next
analyzed the tumors of our previous mouse xenograft ex-
periment for the expression of WIF1. We found that the
A
B C
Fig. 2 MRx102 inhibits lung cancer tumor formation comparable to triptolide. a Mice were subcutaneously injected with H460 cells. Representative
tumors from NSG mice that were treated with either PBS (control), 0.5 mg/kg triptolide, or 1 mg/kg MRx102. b Quantification of tumor volume from
mice in (A). c Quantification of tumor weight from mice in (A). No less than 7 mice were used and p-values were determined using one-way Anova
with a Tukey post test. * and ** represent p values of < .05 and <0.01, respectively, and are derived from a comparison between the control and
treated groups
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tumor tissue from mice that had been treated with
MRx102 had significantly increased WIF1 expression
(Fig. 4b). We further wanted to elucidate a possible mech-
anism for the increase in WIF1 expression. As we previ-
ously stated, we found that triptolide decreases WIF1
promoter methylation, so we conducted PCR using WIF1
methylated and unmethylated specific primers with bisul-
fite converted genomic DNA. In both A549 and H460
cells, treatment with MRx102 decreased methylation at
the WIF1 promoter and increased the unmethylated
population (Fig. 4c). This data suggests that MRx102 in-
creases WIF1 expression by epigenetic modulation.
To investigate the efficacy of MRx102 on patient tumor
tissue, we subcutaneously implanted NSCLC tissue from
patients with either low or high WIF1 expressing tumors
by RT-PCR and western blot analysis into NSG mice
(Fig. 4d). We found that the patient tumors that expressed
low WIF1 levels were sensitive to 3 mg/kg MRx102
(p < .0005) while there was little effect of MRx102 treat-
ment in a high WIF1 expressing PDX (Fig. 4e and f). In
the low WIF1 expressing tumors, MRx102 both alone and
in combination with cisplatin treatment had a greater ef-
fect than cisplatin treatment alone (Fig. 4e). Finally, after
treatment with MRx102, there was an increase in WIF1
and phospho-β-catenin protein expression in the low
WIF1 expressing PDX suggesting that there is a decrease
in Wnt pathway activity after treatment (Fig. 4g). These
data suggests that MRx102 could have a positive impact
on patients whose tumors have low WIF1 expression levels
and that Wnt pathway activity could be used as a bio-
marker for the use of MRx102 as a targeted therapy. These
data also indicates that low WIF1 expression may be an
important marker for sensitivity to MRx102 effects in lung
cancer patients.
Migration and Invasion of NSCLC cells is inhibited by
MRx102 treatment
To study if MRx102 has an effect on lung cancer cell
migration, we plated H460 and A549 cells that had been
treated with 10nM MRx102 for 48 h on fibronectin
coated Transwell filters and allowed the cells to migrate
for 6 h. Cells treated with MRx102 migrated significantly
less than the DMSO control cells (Fig. 5a and b). The
adhesion of both the treated and control cells to fibro-
nectin was similar indicating that MRx102 does not alter
A
B C
Fig. 3 Treatment of xenograft lung cancer cells with MRx102 and carboplatin has an additive effect. a Representative tumors from NSG mice
injected with H460 cells and treated as indicated. b Tumor volume measurements from NSG mice (A) treated with varying concentrations of
MRx102, carboplatin, or a combination of MRx102 and carboplatin. c Quantitative measurement of tumor weight from NSG mice (A) treated as
indicated. No less than 9 mice were used and p-values were determined using one-way Anova with a Tukey post test. **, ***, and **** represent
p values of <0.01, <.001, and < .0001, respectively, and are derived from a comparison between the control and treated groups
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the ability of cells to adhere to the extracellular matrix
(data not shown).
Cancer progression is dependent upon the ability of
cells to degrade and invade the extracellular matrix com-
ponents surrounding the tumor [21]. To investigate if
MRx102 can alter lung cancer cell invasion, we used
Matrigel coated Transwell chambers and allowed the
NSCLC cells to invade for 24 h. We found that MRx102
significantly decreases lung cancer cell invasion through
Matrigel compared to the control cells (Fig. 5c and d).
This data suggests that MRx102 could potentially inhibit
cancer cell migration and invasion in vivo.
MRx102 decreases NSCLC metastasis in mice
Because both lung cancer cell migration and invasion
are significantly altered by MRx102 treatment in vitro,
we next wanted to examine the effect of MRx102 treat-
ment on metastasis in vivo. NSG mice injected with H460
and A549 cells through the tail vein were used as a model
for lung cancer cell metastasis. Mice treated with 3 mg/kg
MRx102 had significantly less metastatic lesion formation
in the lungs (p < .0001) and liver (p = .0065 and p = .0443)
than the vehicle control mice (Fig. 6a and b). This data in-
dicates that MRx102 could be a potential lung cancer
therapeutic for targeting lung cancer progression.
Discussion
Triptolide is a natural product that has been shown to be
an effective anti-inflammatory and anti-tumor compound
[8]. Though triptolide has potent effects in pre-clinical
studies, the development of triptolide into a useful cancer




Fig. 4 Patient tumors expressing high Wnt3a levels are sensitive to MRx102 treatment. a TOP-Flash Wnt activity assay in MRx102 treated H460
(left) and A549 (right) cells. b Western blot analysis of WIF1 expression in H460 mouse xenograft tumors. c WIF1 promoter methylation status in
H460 and A549 cells treated with MRx102. d RT-PCR (top) and western blot (bottom) analysis of WIF1 expression in the patient-derived xenograft
tissue. e Patient tumor expressing low WIF1 shows decreased tumor volume (top) and weight (bottom) when treated with 3 mg/kg MRx102 compared
to 6 mg/kg cisplatin treatment alone. f High WIF1 expressing patient tumor does not respond to MRx102 treatment. Tumor volume (top), tumor
weight (bottom). n = 7. g Western blot analysis of WIF1, phospho-β-catenin, and total β-catenin in the patient-derived xenograft tissue treated with
3 mg/kg MRx102 compared with control tumors. p values were determined using a Student t-test or one-way Anova with a Tukey post test. *, **,
and *** represent p values of < .05, <0.01, and < .001, respectively, and are derived from a comparison between the control and treated groups
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and toxicity profile [15]. The toxicity of triptolide has led
to the development of derivatives that are being tested for
having a similar effect as triptolide without the unwanted
toxicity. One of these triptolide derivatives is MRx102.
MRx102 is converted to triptolide during in vivo treat-
ment and was found to have a similar mechanism of ac-
tion compared to triptolide [16]. Here we have shown that
MRx102 significantly decreases NSCLC cell proliferation,
migration, and invasion. MRx102 also leads to increased
apoptosis in H460 cells through upregulation of p53 and
decreased Akt activity. In addition to its anti-proliferative
effects in vitro, MRx102 is also effective in reducing tumor
formation and metastasis in NSG mice injected with
NSCLC cells.
Canonical Wnt pathway signaling is crucial for proper
embryonic development by controlling cell migration,
proliferation, and differentiation [22]. Wnt pathway com-
ponents also facilitate the maintenance of the adult stem
cell population [23]. Aberrant activation of these compo-




Fig. 5 MRx102 decreases lung cancer cell migration and invasion. a Representative images of migrated H460 (top) and A549 (bottom) cells
treated with either DMSO control (left) or 10nM MRx102 (right) stained with Prolong Gold with DAPI. b Quantitative measurement of migrated
cells in (A). c Representative images of invasive H460 (top) and A549 (bottom) cells treated with either DMSO control (left) or 10nM MRx102 (right)
stained with Prolong Gold with DAPI. d Quantitative measurement of invasive cells from (C). n = 27 20x fields per group. *** represents a p value
of <0.001 as determined by a Student t-test
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thought to contribute to the carcinogenesis of many ma-
lignancies including NSCLC [24, 25]. Promoter hyperme-
thylation and downregulation of WIF1, a secreted Wnt
inhibitor that modulates Wnt activity by directly binding
to Wnt ligands, is thought to be critical for lung cancer
progression and is a prognostic biomarker for patient sur-
vival [26]. We found that MRx102 decreases Wnt pathway
activation and increases WIF1 expression. Notably, we de-
termined that the increase in WIF1 expression was due to
changes in epigenetic modification at the WIF1 promoter
region. Importantly, we discovered that MRx102 has
the greatest efficacy in lung cancer cell lines with low
WIF1 expression. Also patient tissue that has low ex-
pression of WIF1 was more sensitive to MRx102 treat-
ment than tumors with high WIF1 expression. The
ability of MRx102 to target the Wnt pathway and the
sensitivity of WIF1 downregulated tumors to MRx102
treatment could lead to MRx102 as a viable thera-
peutic for patients who have low expression of this in-
hibitory factor.
We did not observe any adverse effects, including no
change in weight or activity level, with 2–4 mg/kg MRx102
treatment administered by IP injection 5 days a week. The
time lengths of treatment varied from 3 to 8 weeks, so it is
possible that there may be treatment-related adverse effects
during prolonged treatment. Taken together, MRx102 ap-
pears to be well tolerated at higher doses compared to
triptolide.
Conclusion
In summary, we found that MRx102 treatment decreases
lung cancer cell proliferation, tumor formation, and me-
tastasis and can work synergistically with platinum based
therapy. We have also shown that cell lines and patient
tissue with low WIF1 expression are more sensitive to
MRx102 treatment than high expressing cells and tissue.
These studies establish that MRx102 is a potent anti-




Fig. 6 Metastatic lesion formation is inhibited by MRx102 treatment. a Representative whole organ imaging and H&E tissue staining of NSG mice
injected with H460 (top grouping) and A549 (bottom grouping) cells. Lung (left) and liver (right) images with corresponding pathological analyses. In
each H&E stain grouping top-left – control (PBS) treatment at 5x magnification, bottom-left - control (PBS) treatment at 20x magnification, top-right –
MRx102 (3 mg/kg) treatment at 5x magnification, and bottom-right – MRx102 (3 mg/kg) treatment at 20x magnification. b Quantification of H460 (left
grouping) and A549 (right grouping) metastatic colony formation in lung (left) and liver (right) from tail-vein injected NSG mice. n = 8 mice, *, **, and
*** represents p values of < .05, <.01, and <0.001 as determined by a Student t-test
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